FY2027 EPS Estimates for BeiGene, Ltd. Raised by Analyst (NASDAQ:BGNE)

BeiGene, Ltd. (NASDAQ:BGNE - Free Report) - Analysts at Leerink Partnrs upped their FY2027 earnings estimates for BeiGene in a report released on Wednesday, May 8th. Leerink Partnrs analyst A. Berens now expects that the company will earn $7.76 per share for the year, up from their prior forecast of $7.32. The consensus estimate for BeiGene's current full-year earnings is ($8.90) per share.

BeiGene (NASDAQ:BGNE - Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($2.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.07) by $0.66. The business had revenue of $751.70 million during the quarter, compared to analyst estimates of $670.09 million. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The firm's revenue was up 67.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($3.34) earnings per share.

A number of other equities analysts have also issued reports on BGNE. TD Cowen boosted their target price on shares of BeiGene from $236.00 to $254.00 and gave the stock a "buy" rating in a research report on Thursday. Bank of America decreased their price target on shares of BeiGene from $179.30 to $164.30 and set a "neutral" rating on the stock in a research note on Monday, April 8th. JPMorgan Chase & Co. raised their price target on BeiGene from $184.00 to $186.00 and gave the company an "overweight" rating in a report on Tuesday, March 19th. Sanford C. Bernstein reduced their price objective on shares of BeiGene from $196.00 to $161.00 and set a "market perform" rating for the company in a research note on Wednesday, March 27th. Finally, Guggenheim dropped their target price on shares of BeiGene from $350.00 to $345.00 and set a "buy" rating on the stock in a report on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, BeiGene presently has a consensus rating of "Moderate Buy" and an average target price of $251.93.

BeiGene Stock Down 4.5 %

Shares of NASDAQ BGNE traded down $7.51 during mid-day trading on Friday, reaching $161.13. The company had a trading volume of 196,355 shares, compared to its average volume of 251,992. BeiGene has a 12-month low of $126.97 and a 12-month high of $245.74. The stock has a fifty day moving average of $154.90 and a two-hundred day moving average of $166.49. The company has a market capitalization of $15.41 billion, a price-to-earnings ratio of -18.96 and a beta of 0.63. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.09 and a current ratio of 2.32.

Institutional Trading of BeiGene

Hedge funds have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. lifted its holdings in shares of BeiGene by 17.9% during the third quarter. Baillie Gifford & Co. now owns 3,871,598 shares of the company's stock worth $696,384,000 after purchasing an additional 588,294 shares during the period. Capital International Investors lifted its holdings in shares of BeiGene by 4.7% during the fourth quarter. Capital International Investors now owns 6,336,872 shares of the company's stock worth $1,142,636,000 after purchasing an additional 285,397 shares during the period. First Trust Advisors LP acquired a new position in shares of BeiGene during the fourth quarter worth $39,632,000. M&G Plc acquired a new position in shares of BeiGene during the first quarter worth $29,649,000. Finally, Goldman Sachs Group Inc. raised its stake in BeiGene by 175.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company's stock worth $38,658,000 after buying an additional 136,458 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company's stock.

Insider Buying and Selling

In other BeiGene news, CFO Julia Aijun Wang sold 397 shares of the firm's stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The sale was disclosed in a document filed with the SEC, which is available at this link. In other BeiGene news, CFO Julia Aijun Wang sold 397 shares of the firm's stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO John Oyler sold 26,716 shares of the firm's stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the completion of the sale, the chief executive officer now owns 12,084 shares in the company, valued at approximately $1,799,186.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,781 shares of company stock worth $10,222,381. Corporate insiders own 7.40% of the company's stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.